Background
==========

SURF1 deficiency is a recessively inherited mitochondrial disorder and is the most frequent cause of Leigh syndrome (LS) associated with cytochrome *c* oxidase (COX, complex IV) deficiency. COX is the fourth complex of the mitochondrial oxidative phosphorylation (OXPHOS) system where sequential electron transfer is coupled to proton pumping by complexes I-IV. The electrochemical gradient generated is ultimately used by complex V (ATP synthase) to synthesise ATP from ADP and inorganic phosphate. A number of assembly factors are required for the intricate biogenesis of the COX holoenzyme and studies in *Paracoccus denitrificans* and *Saccharomyces cerevisiae* have identified SURF1 as a key player in the early assembly of COX \[[@B1],[@B2]\].

Due to their clinical and genetic heterogeneity, mitochondrial diseases are often a diagnostic challenge. LS, a fatal subacute necrotising encephalomyelopathy, is a genetically heterogeneous mitochondrial disorder which can be associated with any OXPHOS deficiency \[[@B3]\]. Since *SURF1* mutations were linked to COX deficiency and LS in 1998 \[[@B4],[@B5]\] isolated case reports and mutation series have been reported \[[@B6],[@B7]\]. However a collective description depicting the natural history with biochemical and radiological features of this disease has not yet been published. The disease features of SURF1 deficiency are not widely recognized by paediatricians and a clear understanding of the clinical continuum of the disease is important to improve diagnosis of this condition. Affected families often enquire about prognosis, but there is limited data in the literature to provide prognostic information. Well-documented natural history studies are also an invaluable aid to planning future clinical trials.

We sought to characterise the phenotypic and genotypic spectrum of SURF1 deficiency, to provide survival data in a large cohort, and highlight clinical predictors of longer survival. We also report 5 novel mutations and review all the cases published in the literature.

Materials and methods
=====================

We conducted a multi-centre case notes review of all patients diagnosed since 1998, when *SURF1* mutations were first linked to LS. All SURF1-deficient patients were identified through the NHS Specialized Services-funded mitochondrial molecular diagnostic laboratory in Oxford which provides a national diagnostic service for *SURF1* in the UK, and through the major Australasian paediatric diagnostic centre (Murdoch Childrens Research Institute, Melbourne). All subjects with a confirmed genetic diagnosis of SURF1 deficiency, defined as two pathogenic variants in the *SURF1* gene, were considered eligible. We also included patients who died before the *SURF1* gene was identified, if subsequent analysis of stored samples revealed two pathogenic *SURF1* mutations. Where stored samples were unavailable, we included deceased patients if they had an affected sibling with a confirmed *SURF1* mutant genotype and a similar disease course.

Clinical data including the age-of-onset of symptoms, neuroimaging, nerve conduction studies, muscle histology and histochemistry, blood lactate, CSF lactate, and respiratory chain enzyme (RCE) activities in muscle and cultured skin fibroblasts, were collected using a structured questionnaire completed by the responsible clinician at each centre. The questionnaire (Additional file [1](#S1){ref-type="supplementary-material"}) was developed and tested in a pilot study conducted at Great Ormond Street Hospital, London, UK on ten patients with genetically confirmed SURF1 deficiency.

All genetic studies were performed with informed consent of parents/legal guardians of the patients. Ethical approval for the study was obtained from the National Research Ethics Committee London Bloomsbury, UK and the Royal Children's Hospital Human Research Ethics Committee, Melbourne, Australia (HREC 32188A).

Systematic literature review
----------------------------

To identify previously published cases a systematic literature search was conducted in PubMed in January 2013 using the search terms "SURF1", "SURF-1", "Leigh syndrome", "cytochrome c oxidase deficiency", "complex IV deficiency", and "Cox deficiency". The search was limited to studies in humans published after 1.1.1998 (the year SURF1 deficiency was first described). There were no language restrictions. Of 2135 identified records, 1969 were excluded based on review of titles, 110 were excluded on the basis of abstracts, and 56 full-text records were retrieved. Of these, 43 records describing 129 cases with SURF1 deficiency were reviewed. Bibliographies were searched manually for additional records. The cases were used to ascertain previously identified phenotypes and genotypes, to draw phenotype and genotype comparisons between our cohort and previously published cases and for Kaplan**-**Meier survival analysis. These cases were not included in our natural history analysis, as data was incomplete and the chronological onset of symptoms was not available in many of the published cases. Authors were contacted and raw data was obtained for survival rates of LRPPRC-deficient LS patients \[[@B8]\] and nuclear-encoded complex I-deficient LS patients \[[@B9]\].

Statistical analysis
--------------------

Kaplan**-**Meier survival analysis was used to compare survival rates for the SURF1 deficiency, LRPPRC-deficient LS and nuclear-encoded complex I-deficient LS patients. Mortality rates were compared using the log rank test. Statistical analysis was performed using Stata 12.1 software (Stata, College Station, Tex).

Results
=======

Demography
----------

We identified 57 patients with SURF1 disease born between 1976 and 2010, diagnosed at ten centres in the UK (n = 52) and two centres in Australia (n = 5). Genotypes were established in 54 patients and 3 deceased patients were assumed to have the same genotype as their affected sibling with SURF1 deficiency since they had a similar disease course. Detailed clinical data were available in 45 patients. It was not possible to trace clinical records and/or the responsible clinician in the remaining 12 cases. One patient from a consanguineous pedigree was found to have genetically confirmed Zellweger syndrome in addition to SURF1 disease (homozygous c.799_800delCT) and was excluded from further analyses. The study group consisted of 44 patients (24 males, 55%) from 37 pedigrees, with 10 (23%) patients from consanguineous families. Of these, 4 cases (cases 1b, 30, 35 and 36 in Table [1](#T1){ref-type="table"}) have been published \[[@B3],[@B10],[@B11]\]. White Europeans formed the largest ethnic group (n = 20, 45%) followed by Bangladesh Bengali (n = 5, 11%), Indian Gujarati (n = 5, 11%) and Pakistani (n = 4, 9%). Other ethnicities included Turkish Cypriot (n = 2), Chinese (n = 1), Sri Lankan (n = 1) and six cases where the ethnicity was not specified.

###### 

Clinical features and genotypes of 44 patients with SURF1 deficiency

  **Case**   **Gender**   **Consanguinity**   **Clinical features**                                                                                                                                 **Age at onset\* (months)**   **Age at death\* (months)**   **Skeletal muscle histology/histochemistry**   **Muscle COX**   **Fibroblast COX activity**   **Abnormal regions on neuroimaging**                                                             ***SURF1*Mutations**
  ---------- ------------ ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------- ---------------------------------------------- ---------------- ----------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------
  1a         M            Yes                 PF/V, PW, nystagmus, RF                                                                                                                               8                             2y 1 m                        NA                                             NA               29% of LLR                    Cp, tectal plate, PAG, Icp, Ion, Dt, corticospinal tracts                                        Homo c.792_793delAG
  1b         F            Yes                 PW, hypotonia, DR, DD, hypertrichosis, nystagmus, RF                                                                                                  9                             3y                            T1FP, increased lipid                          Low              UD                            Leukoencephalopathy: WM, posterior limbs of IC, Cc, Dt, cerebellar WM                            Homo c.792_793delAG
  2          F            No                  Ataxia, hypotonia, nystagmus, ophthalmoplegia, PW, tremor                                                                                             18                            Alive 12y                     Smaller T1 fibres                              Low              19% of LLR                    Pu, Me, Ico                                                                                      c.240+1G \>T, c.575G\>A
  3          F            No                  DD, hypotonia, nystagmus, PW, tremor, ophthalmoplegia, ataxia                                                                                         birth                         Alive 19y                     Normal                                         Low              37% of LLR                    Mb, pons                                                                                         c.312_320del10insAT, c.751+5G\>A
  4          F            No                  PF, movement disorder, PW, DD, RF                                                                                                                     7                             16                            NA                                             Low              57% of LLR                    NA                                                                                               Homo c.312_320del10insAT
  5a         M            No                  PF, ataxia, nystagmus. ophthalmoplegia, tremor, PW, DR, RF                                                                                            10                            5y 2 m                        Absent COX, increased lipid                    Low              UD                            Dt, Cd, Mb, Me                                                                                   Homo c.516-2A\>G
  5b         M            No                  PF/V DD, DR, RF                                                                                                                                       3 days                        20                            Increased lipid                                NA               NA                            At 1y: normal                                                                                    Homo c.516-2A\>G
  6          M            No                  V, PW, hypotonia, DR, ophthalmoplegia, ataxia, encephalopathy                                                                                         9                             21                            Increased lipid, reduced COX                   NA               12% of LLR                    Dt, dorsal BS, Cp, STh                                                                           Homo c.324-11T\>G
  7          M            No                  V, PW, DR, tremor, nystagmus, hypotonia, ophthalmoplegia, ataxia                                                                                      10                            4y                            Increased lipid                                NA               27% of LLR                    Th, Cd, GP BS, cerebellum                                                                        Homo c.312_320del10insAT
  8a         F            No                  Hypertrichosis, DD, ataxia, hypotonia, nystagmus, ophthalmoplegia, encephalopathy, PF, OA, RF                                                         9                             11y 9 m                       Reduced COX, T1FP, increased lipid             NA               UD                            CT brain: GP and cerebellar atrophy                                                              Homo c.516-2A\>G
  8b         F            No                  V, DD, PW, hypertrichosis, hypotonia, nystagmus, ophthalmoplegia, ataxia, RF                                                                          10                            6y 6 m                        NA                                             NA               NA                            CT brain: normal                                                                                 Homo c.516-2A\>G
  9a         M            No                  V, PW, DD nystagmus, ophthalmoplegia, hypotonia                                                                                                       2                             24 m                          Increased lipid, reduced COX.                  NA               27% of LLR                    CT brain: normal                                                                                 Homo c.312_320del10insAT
  9b         F            No                  Hypotonia, PF/V, PW, DD, hypertrichosis, motor delay, ophthalmoplegia, RF, OA                                                                         1.5                           4y                            NA                                             NA               NA                            CT brain: widened subarachnoid spaces                                                            Homo c.312_320del10insAT
  10         M            Yes                 Hypotonia, PF/V, DD, nystagmus, PW, ataxia, RF                                                                                                        4                             24 m                          T1FP                                           Low              50% of LLR                    NA                                                                                               Homo c.516-2A\>G
  11         F            Yes                 DD, DR, PF/V, PW, tremor, OA, PW, hypotonia, nystagmus, ataxia, RF                                                                                    9                             7y 1 m                        Absent COX increased lipid, T1FP               NA               7% of LLR                     Mb, Dt, Cd, GP                                                                                   Homo c.751C\>T
  12         M            No                  PF/V, DD, DR, hypotonia, encephalopathy, PW, RF                                                                                                       6                             13 m                          NA                                             NA               NA                            Cd, Pu, BS                                                                                       Homo c.312_320del10insAT, c.688C\>T
  13a        F            Yes                 DD, DR, PF/V, nystagmus, dystonia, PW, Sz, hypertrichosis, RF                                                                                         12                            5y 5 m                        T1FP, Reduced COX                              Low              53% of LLR                    Me, Cc, cerebellar atrophy, multicystic changes in peritrigonal regions, posterior limbs of IC   Homo c.324-11 T\>G
  13b        F            Yes                 PF/V, PW, hypotonia, DD, DR                                                                                                                           15                            Outcome unknown               NA                                             Low              NA                            NA                                                                                               Homo c.324-11 T\>G
  14         F            Yes                 DD, DR, hypotonia, PF/V, chorea, PW, nystagmus                                                                                                        18                            Outcome unknown               Reduced COX, increased lipid                   Low              UD                            BG, BS, long tracts                                                                              Homo c.792_793delAG
  15         M            No                  Hypotonia, DD, DR, dystonia, ophthalmoplegia, PF/V, RF                                                                                                2y 6 m                        4y 6 m                        Reduced COX, T1FP                              Low              UD                            BS, Calcification of Dt, Cd, GP                                                                  Homo c.312_320del10insAT
  16         M            Yes                 PF/V, PW, hypotonia, DD, DR, encephalopathy, RF                                                                                                       9                             18 m                          Reduced COX.                                   Low              17% of LLR                    BS, Dt, SN, Pu, GP, Cd, Cc, cystic changes in Dt, BG and central WM                              Homo c.324-11T\>G
  17         M            No                  Short stature, ataxia, PW, hypertrichosis, nystagmus, DD                                                                                              5y                            Alive 15y                     Increased lipid, reduced COX                   Low              NA                            Dt and cerebellar atrophy                                                                        Homo c.312_320del10insAT
  18         F            Yes                 PF/V, DR, PW, DD, hypotonia, tremor, dystonia, OA, ophthalmoplegia                                                                                    10                            8y 9 m                        Absent COX T1FP                                Low              40% of LLR                    Leukoencephalopathy: WM abnormalities in cerebral hemispheres and cerebellum                     Homo c.833+1G\>A
  19         M            No                  Hypotonia, PF/V, PW, choreoathetoid movements, dystonia, DR, RF                                                                                       10                            3y 6 m                        Reduced COX T1FP                               Low              NA                            Cd, Cd, GP Cp, SN.                                                                               Homo c.312_320del10insAT
  20         M            No                  Hypotonia, apnoeic episodes, motor delay, ataxia, DR, DD, tremor, hypertrichosis, dystonia, PF/V, PW, RF ophthalmoplegia, nystagmus, hypertrichosis   10                            Alive 16y                     Reduced COX                                    Low              NA                            At 1y: normal                                                                                    Homo c.704C\>T
  21a        M            No                  V, PW, generalized hypotonia, nystagmus, ophthalmoplegia, DD, encephalopathy, RF                                                                      10                            2y 3 m                        Absent COX, increased lipid                    Low              23% of LLR                    Pu, ventral Me, cervico-medullary region                                                         Homo c.792_793delAG
  21b        M            No                  PF/V, PW, DD, DR, hypotonia, OA, ophthalmoplegia, nystagmus, hypertrichosis, RF                                                                       9                             2y 5 m                        NA                                             NA               NA                            NA                                                                                               Homo c.792_793delAG
  22         M            No                  DD, DR, PW, ataxia, dysarthria, choking episodes, V, hypotonia, nystagmus, hypertrophic cardiomyopathy                                                4y 3 m                        Outcome unknown               Absent COX                                     Low              NA                            Deep grey matter involvement of cerebellum, Mb, Pu                                               c.240+1G\>T, c.574C\>T
  23         F            No                  PF/V, DR, DD, PW, hypotonia, nystagmus, tremor, dystonia, hypertrichosis, ophthalmoplegia, encephalopathy, ataxia, RF                                 15                            21 m                          Absent COX                                     Low              NA                            Cc, Mb, BS, GP                                                                                   Homo c.312_320del10insAT
  24         F            No                  PW, V, hypertrichosis, DD, hypotonia, ophthalmoplegia, tremor, Sz, ataxia, encephalopathy, RF                                                         2                             2y 10 m                       Absent COX                                     Low              NA                            Thalamic fasciculus, RN, Mb, pons, Scp, Dt, Me, WM tracts of spinal cord                         Homo c.324-11T\>G
  25a        M            No                  PW, DD, ataxia, falls, OA, hypotonia, hypertrichosis, ophthalmoplegia, nystagmus, ataxia, RF                                                          20                            14y                           NA                                             NA               NA                            Me, Icp, pons. Linear area in the periventricular WM of both occipital lobes                     Homo c.871insT
  25b        M            No                  DD, PF/V, PW, choreoathetosis, ataxia, hypotonia, OA, encephalopathy, ataxia, RF                                                                      24                            11y                           Normal                                         NA               30% of LLR                    Cd, GP                                                                                           Homo c.871insT
  26         M            No                  Hypotonia, V, PW, ophthalmoplegia, DD, nystagmus, dyskinesia, choreoathetoid movements, RF                                                            2                             3y 10 m                       Increased lipid                                NA               UD                            Cd, Cd, GP, deep WM in cerebellar hemispheres                                                    c.312_320del10insAT, c.240+1G\>T
  27         M            No                  DD, hypotonia, PF, PW, DR, RF                                                                                                                         10                            4y 9 m                        Reduced COX                                    Normal           UD                            CT brain: BG                                                                                     c.845_846delCT, c.240+1G\>T
  28         F            No                  Hypotonia, PF/V, PW, hypertrichosis, DD, DR, encephalopathy, nystagmus                                                                                3                             Alive 24 m                    NA                                             NA               NA                            Me, medial aspect of the cerebellar peduncles, Dt, Pu, Cp, PAG                                   Homo c.312_320del10insAT
  29         F            Yes                 PF, PW                                                                                                                                                birth                         24 m                          NA                                             NA               17% of LLR                    NA                                                                                               Homo c.799_800delCT
  30         M            No                  PW, DD, tremor, hypertrichosis. Post operative V, ophthalmoplegia, hypotonia                                                                          9 days                        5y                            NA                                             Low              NA                            Ion, inferior pons, STh, Pu, spinocerebellar tracts, Icp, PAG, Dt, cerebellar WM                 c.312_320del10insAT, c.871insT
  31         F            No                  PF/V, PW, DD, DR, tremor                                                                                                                              1.5                           3y 7 m                        Normal                                         Low              NA                            RN, Scp, PAG, Dt, deep cerebellar WM, Me, Ion, optic radiation                                   Homo c.792_793delAG
  32         F            No                  PW, DD, DR, PF, hypotonia                                                                                                                             12                            2y 3 m                        Increased lipid                                Low              NA                            Mb, pons, Me, Icp, Dt, Cc, Cd, Pu, cerebellar WM, STh, SN,IC, long tracts in cervical spine      Homo c.754_755delAG
  33         M            No                  PF, PW, hypertrichosis, ataxia, DR, hypotonia, tremors, nystagmus, OA                                                                                 14                            7y 2 m                        Reduced COX                                    Low              32% of LLR                    Me, spinal cord, Pu, SN, IC, medullary pyramidal decussation, middle cerebellar peduncle         Homo c.312_320del10insAT
  34         M            No                  PW, PF/V, DD, DR, hypertrichosis, tremor, hypotonia, ophthalmoplegia, ataxia, RF, Sz                                                                  13                            24 m                          Absent COX increased lipid                     Low              NA                            Th, Mb, dorsal pons, Me                                                                          c.312_320del10insAT, c.574insCTGC
  35         F            No                  PW, PF/V, DD, DR, hypertrichosis, hypotonia, ophthalmoplegia, OA, nystagmus, tremor, ataxia, RF, Sz                                                   9                             2y 6 m                        Absent COX, increased lipid                    Post mortem      12% of LLR                    Th                                                                                               c.312_320del10insAT, c.751C \>T
  36         F            No                  PW, PF/V, DD, DR, hypertrichosis, hypotonia, ophthalmoplegia, OA, nystagmus, tremor, ataxia, RF, Sz,                                                  15                            7y 10 m                       Reduced COX, increased lipid                   Post mortem      44% of LLR                    CT brain: Pu                                                                                     c.312_320del10insAT, c.688C\>T
  37         M            No                  PF, ophthalmoplegia ataxia, hypotonia,Gross motor delay, PW, DR, DD, RF, Sz, hypertrichosis                                                           birth                         6y                            Reduced COX                                    Low              NA                            STh                                                                                              c.312_320del10insAT, c. 752 -2A\>G

\*Age in months unless otherwise stated; a, b denote siblings; y/m years and months; NA not available.

Key to clinical and neuroimaging features: *BG* basal ganglia, *BS* Brain stem, *Cc* corpus callosum, *Cd* Caudate nucleus, *COX* cytochrome *c* oxidase, *Cp* cerebral peduncle, *Cst* corticospinal tracts, *DD* developmental delay, *DR* developmental regression, *Dt* Dentate, *Homo* homozygous, *GP* Globus pallidus, *IC* internal capsule, *Ico* Inferior colliculus, *Ion* inferior olivary nucleus, *Icp* inferior cerebellar peduncle, *LLR* lower limit of reference range, *Mb* Midbrain, *Me* Medulla, *NA* not available, *PAG* periaqueductal gray matter, *PF* poor feeding, *Pu* Putamen, *PW* poor weight gain, *RF* Respiratory failure, *RN* Red nucleus, *OA* optic atrophy, *Sco* superior colliculus, *Scp* superior cerebellar peduncle, *SN* Substantia Nigra, *STh* Subthalamic nucleus, *Sz* Seizures, *T1* type 1 muscle fibres, *T1FP* Type 1 muscle fibre predominance, *T2* type 2 muscle fibres, *Th* Thalamus, *UD* undetectable, *V* vomiting, *WM* white matter.

Initial symptoms
----------------

The median age for the onset of first symptoms was 9.5 months (range 0--60 months) and the majority of the patients presented in the first year (32/44, 73%). The most frequently noted initial symptoms were poor feeding/vomiting (frequently attributed to gastro-oesophageal reflux) and poor weight gain (Table [2](#T2){ref-type="table"}). The neonatal period was uneventful in the majority of patients (41/44, 93%) except in two patients with feeding problems and one patient with hypotonia. Developmental regression, defined as a loss of cognitive or motor skills, was the initial symptom in 3/44 (7%) patients. Most patients (26/44, 59%) presented with a combination of gastro-intestinal symptoms, poor weight gain and hypotonia. Three patients who underwent a general anaesthetic in the first two months experienced significant problems during the recovery period. One patient (case 30), who had surgery for transposition of the great arteries on day 9, developed persistent vomiting and required enteral feeding. The second patient (case 26) became hypotonic following surgery for pyloric stenosis at 8 weeks. The third patient (case 4) developed a movement disorder after an upper gastro-intestinal endoscopy.

###### 

Initial symptoms in 44 patients with SURF1 deficiency

  **Initial symptoms**       **Number of patients (%)**   **Age range of initial presentation (months)**
  -------------------------- ---------------------------- ------------------------------------------------
  poor feeding/vomiting      20 (46)                      0-24
  poor weight gain           19 (43)                      1.5-20
  developmental delay        10 (23)                      9-51
  hypotonia                  9 (21)                       0-10
  movement disorder          3 (7)                        10-24
  developmental regression   3 (7)                        10-18
  ataxia                     2 (5)                        14-60

Major clinical features
-----------------------

Review of 44 cases with SURF1 deficiency revealed that 32 patients met the criteria for Leigh syndrome \[[@B3]\] and 12 patients were classified as "Leigh-like" due to atypical or normal radiological features or where neuroimaging was not available. The development of clinical features over time is demonstrated in Figure [1](#F1){ref-type="fig"}. Poor weight gain and hypotonia were the most prevalent symptoms, and tended to be preceded by gastro-intestinal symptoms such as poor feeding/vomiting (Figure [1](#F1){ref-type="fig"}). Long term enteral feeding was required in 21/44 (48%). Developmental regression (median age-of-onset 19 months) was noted in 27/38 (71%) cases and was precipitated by an intercurrent viral infection in 12 patients.

![**Clinical features in 44 patients with SURF1 deficiency.** The x axis indicates the age of onset (years) and the y axis indicates the clinical features. Percentages denote the proportion of patients with a given clinical feature, and box-and-whisker plots show the age of onset. The median age of onset is indicated by the vertical line within the boxes. Boxes represent upper and lower quartiles, whiskers represent extreme values, and dots represent outliers which are ≥1.5 times the interquartile range from the median. Other less commonly observed features included hypertrichosis (41%), optic atrophy (23%), encephalopathy (20%), seizures (14%) and cardiomyopathy (2%).](1750-1172-8-96-1){#F1}

Hypertrichosis was reported in 18/44 (41%) patients. There was no significant correlation between the presence of hypertrichosis and lactic acidosis. Nystagmus and ophthalmoplegia were found in 25/42 (60%) and 22/42 (52%) patients, respectively, and occurred later (median age-of-onset 29 months). Movement disorder was noted in 22/42 (52%) patients (median age-of-onset 2 years) with an isolated intention tremor in 13 patients, choreoathetoid movements in 3, and dystonia in 2, while 4 patients demonstrated a combination of these abnormal movements. Only 6/44 (14%) patients reported seizures (generalised tonic clonic 5, myoclonic 1) and 4 of these patients were from Australia. Other less frequent clinical features included optic atrophy in 10/44 (23%), encephalopathy in 9/44 (20%) and hypertrophic cardiomyopathy in 1/44 (2%). None of the patients were reported to have pigmentary retinopathy or sensorineural deafness.

Biochemical data
----------------

CSF lactate was elevated in all subjects who had this measured (mean 4.3, range 2.5-8.6 mmol/L, normal \<2 mmol/L). Metabolic acidosis was present in 21/33 (64%) patients (mean bicarbonate level 14.7, range 10--17 mmol/L). 31/38 (81%) patients had elevated blood lactate (mean 4.4, range 2.3-7.3 mmol/L) (Table [3](#T3){ref-type="table"}). Fibroblast COX activity was found to be low in all subjects who were tested (25/25, 100%) and ranged from levels below the detection limit of the assay, to 57% of the lower limit of the reference range (reference range 30--90 nmol/mg protein/min).

###### 

Laboratory and magnetic resonance imaging (MRI) findings in SURF1 deficiency

  **Laboratory or neuroimaging finding**   **Number of patients**   **%**
  ---------------------------------------- ------------------------ -------
  **Blood**                                                          
  Metabolic acidosis                       21/33                    64
  Elevated lactate                         31/38                    81
  **Cerebrospinal fluid**                                            
  Elevated lactate                         30/30                    100
  **Muscle**                                                         
  Reduced/absent COX histochemistry        23/33                    70
  Type I fibre predominance                8/33                     24
  Elevated muscle lipid content            16/33                    48
  Reduced muscle COX activity              25/26                    96
  **Fibroblast**                                                     
  Reduced fibroblast COX activity          25/25                    100
  **Nerve conduction studies**                                       
  Peripheral neuropathy                    13/16                    81
  **MRI lesions**                                                    
  Midbrain                                 12/33                    36
  Pons                                     10/33                    30
  Medulla                                  15/33                    45
  Putamen                                  16/33                    48
  Globus pallidus                          14/33                    42
  Caudate nucleus                          12/33                    36
  Subthalamic nucleus                      4/33                     12
  Periaqueductal grey matter               4/33                     12
  Olivary nuclei                           3/33                     9
  Red nuclei                               2/33                     6
  Cerebellar white/grey matter             6/33                     18
  Cerebellar atrophy                       3/33                     9
  Dentate nucleus                          13/33                    39
  Cerebellar peduncles                     8/33                     24
  Leukoencephalopathy                      2/33                     6

Muscle biopsy
-------------

We analysed the histology and RCE findings of all patients where a muscle biopsy was performed (n = 33). Lipid content was increased in 15/33 (46%) of biopsies and type 1 fibre predominance was noted in 8 biopsies. COX histochemistry demonstrated absent COX in 9 (27%) biopsies and reduced COX staining in 14 (42%) biopsies. Ten (30%) of the biopsies were reported to have normal COX histochemistry with uniform staining of all fibres. RCE activities were measured in 28 biopsies. Two post-mortem biopsies were excluded since post-mortem delay may have resulted in artefactual loss of RCE activities. An isolated decrease of COX activity was found in all except one biopsy where the COX activity was at the lower end of the reference range (COX activity/citrate synthase ratio was 0.016 (reference range 0.014-0.034).

Neuroimaging
------------

Magnetic resonance imaging (MRI) and Computerised tomography scan (CT) information was available for 39 subjects (33 MRI and 6 CT scans). The patterns of involvement are shown in Table [3](#T3){ref-type="table"}. Most MRIs showed findings characteristic of Leigh syndrome (28/33, 85%), with symmetrical hyperintense lesions on T2-weighted imaging in the brainstem and/or basal ganglia (Table [3](#T3){ref-type="table"}). Two patients had normal MRI scans which were performed at 1 year of age and follow up imaging was not available. Two patients (one already published, \[[@B10]\]) had leukoencephalopathy (defined as a disorder that predominantly or exclusively affects the white matter of the brain \[[@B12]\]), while one patient had cerebellar atrophy and involvement of the dentate nucleus. Six patients had CT scans of which 3 were found to be normal and three had bilateral symmetric hypodensities in the basal ganglia.

Peripheral nervous system
-------------------------

Sixteen patients had nerve conduction studies performed. Abnormal peripheral nerve conduction was noted in 13/16 (81%) with most (7) demonstrating a demyelinating neuropathy compared to an axonal neuropathy in 2 subjects. The type of neuropathy was unspecified in 4 subjects. Many (9/13, 69%) subjects showed a mixed sensori-motor involvement whereas 2 subjects had a pure sensory neuropathy.

***SURF1*** gene mutations
--------------------------

We identified *SURF1* mutations in 57 patients; 16/57(28%) had the homozygous c.312_320del10insAT insertion/deletion, 15/57(26%) were compound heterozygotes, 12/57(21%) had homozygous splice site mutations, 10/57(18%) had homozygous deletions, 2/57 (4%) had homozygous insertions, 1/57 (2%) had homozygous missense mutations and 1/57(2%) had homozygous nonsense mutations. The most frequently occurring mutation in our cohort was c.312_321del10insAT (p.Leu105X) (16 homozygous and 11 compound heterozygous). The next most common mutations were c.792_793delAG which occurred exclusively in Bangladesh Bengali subjects (n = 5, 3 pedigrees) and the splice mutation c.240+1G\>T which was observed in 5 individuals, all of white European origin. The c.792_793delAG mutation has previously only been described in a patient of Japanese origin \[[@B13]\]. Individuals of Pakistani origin had the novel c.799_800delCT mutation or the c.324-11T\>G mutation. The c.516-2A\>G mutation segregated in two different Indian Gujarati pedigrees and has previously only been described in one subject of unspecified mixed Caucasian Asian parenthood \[[@B7]\]. The c.324-11T\>G genotype was observed in 4 individuals from 2 different Pakistani pedigrees and one individual of Indian Gujarati origin. All five patients from the Australian cohort had at least one c.312_321del10insAT (p.Leu105X) mutation. No specific genotype phenotype correlation was observed. The patients surviving \>10 years had varied *SURF1* genotypes: one was homozygous for the c.312_321del10insAT mutation, two were compound heterozygotes, two had homozygous insertions and one had a splice site mutation.

Novel pathogenic mutations
--------------------------

In our cohort we identified 19 *SURF1* mutations (Figure [2](#F2){ref-type="fig"}) in 57 patients including 5 novel pathogenic mutations (c.468_469delTC, c.799_800delCT, c.575G\>A (p.Arg192Gln), c.751+5G\>A. and c.752-2A\>G).

![**Pathogenic mutations in the human*SURF1*gene.** A schematic diagram of the *SURF1* gene illustrating 83 mutations reported to date. Red: novel unreported mutations identified in this study, blue: other mutations which have been previously reported and found in this study, black: mutations previously reported in the literature.](1750-1172-8-96-2){#F2}

Of the novel mutations identified, the homozygous c.799_800delCT was found in a Pakistani family where the patient (case 29) presented with early onset disease from birth and died at 2 years. The novel splice site c.751+5G\>A mutation, generating an aberrant transcript with incorporation of 31 base pairs of intron 7 into a proportion of mature mRNAs, was found in one subject (case 3) who was a compound heterozygote (c.312_321del10insAT, c.751+5G\>A). She had an atypical milder clinical course with longer survival. Her first concerning symptoms were at 16 months when she was noted to have mild motor delay and ataxia but in retrospect mild hypotonia was present from birth. She subsequently developed nystagmus and external ophthalmoplegia. She is currently studying business studies at 19 years of age. The novel missense mutation (c.575G\>A, p.Arg192Gln) was found in a 12 year old female (case 2) with ataxia and a 4 year old male (case 22) with developmental delay, ataxia and hypertrophic cardiomyopathy. This was the only patient in the cohort with cardiomyopathy. The female patient subsequently developed nystagmus with ophthalmoplegia but she is currently able to ride a bicycle and play the violin. The splice site mutation c.752-2A\>G was found in a patient (case 37) of Australian origin who presented with irritability and poor feeding since birth. Unfortunately clinical information was unavailable for the patient with the homozygous c.468_469delTC mutation.

Survival
--------

Among the 44 patients with detailed clinical data, five were alive at the time of writing (age range 2--19 years) while in three patients the current vital status was not known. Of the 36 deceased patients with known cause of death, the cause was central respiratory failure in 29/36 (80%). Seven patients survived beyond 10 years of age (cases 2, 3, 8a, 17, 20, 25a, 25b in Table [1](#T1){ref-type="table"}). Of these, 6 presented with neurological symptoms such as ataxia and motor developmental delay; of note, gastro-intestinal symptoms were not the prominent presenting feature in these cases. Furthermore, these six patients also did not experience developmental regression.

Literature searches identified 98 SURF1-deficient cases with available survival data, which we pooled together with the data from our 44 cases. In a Kaplan-Meier analysis (Figure [3](#F3){ref-type="fig"}), we compared the survival experience of these 142 SURF1-deficient cases to two other groups with LS due to nuclear gene mutations. We compared the survival of SURF1 deficiency to 56 patients with LRPPRC deficiency \[[@B8]\] and 63 patients with nuclear-encoded complex I-deficient LS/"Leigh- like" disease \[[@B9]\] Median survival length was longer in patients with SURF1 deficiency (median 5.4, 25th centile 3.0, 75th centile 10 years) than in patients with LRPPRC deficiency (median 1.8, 25th centile 1.0, 75th centile 4 years), and nuclear-encoded complex I-deficient LS (median 1.6, 25th centile 1.0, 75th centile 10 years) (p \< 0.001 for difference across groups; logrank test).

![**Kaplan-Meier survival curves comparing SURF1 deficiency, LRPPRC-deficient LS and nuclear-encoded complex I deficient Leigh/Leigh-like syndrome.** Blue line: SURF1 deficient patients, n = 142 (this article and literature), red line: LRPPRC deficient patients, n = 56 \[[@B8]\], green line: complex I deficient Leigh/Leigh-like syndrome n = 63 \[[@B9]\]. Logrank test p \< 0.001.](1750-1172-8-96-3){#F3}

Additional cases in the literature
----------------------------------

A systematic review of the literature revealed published clinical data on 129 SURF1-deficient patients and mutation data in a further 28 cases. The findings are summarised in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1. Features which were found in these patients but not present in our cohort included unspecified hepatic involvement (3 cases), renal tubulopathy (4 cases) and facial dysmorphism (5 patients) \[[@B7],[@B14]-[@B19]\].

Discussion
==========

SURF1 deficiency is the most common single cause of Leigh syndrome in the UK population, and careful documentation of the clinical features may lead to increased recognition and more rapid diagnosis of affected children. The need for early genetic diagnosis can be particularly pressing when affected families seek prenatal diagnosis. Improving the diagnostic process relies on well-recognised clinical features, but often there are inadequate numbers of patients with a single gene disorder of mitochondrial energy metabolism to characterise phenotypes. We have collected a cohort of 57 SURF1-deficient patients with comprehensive phenotypic data on 44 patients. We found that SURF1-deficient patients have a relatively homogenous phenotype which typically commences in late infancy with gastro-intestinal symptoms, followed by episodic neurological regression, ophthalmoplegia, movement disorder, finally leading to death from respiratory failure. Although there is a consistent clinical phenotype, there were no clinical characteristics that allowed discrimination of SURF1 deficiency from other causes of LS, such as complex I deficiency or complex V deficiency.

Cardiomyopathy was rare (one patient), and this observation is similar to the literature where only 2/129 cases had cardiomyopathy \[[@B14],[@B18]\]. Seizure disorders also appeared to be uncommon and were found predominantly in the Australian patients which may indicate an environmental trigger which precipitates seizures. High temperature is unlikely to be the precipitating factor since no seasonal variation in seizures was observed in the cases from Australia. The low incidence of seizures is comparable with cases described previously where only 5% (7/129) were reported to have had seizures. Sensorineural deafness was not found in this SURF1-deficient cohort and is in keeping with the low occurrence in the literature where only two previous cases had sensorineural deafness \[[@B14]\]. Three (2%) cases were previously reported to have optic atrophy \[[@B6],[@B18]\] whereas 10 (23%) of our patients were noted to have optic atrophy. Visual and auditory signs are difficult to ascertain in paediatric practice and may have been underdiagnosed in many cases where formal testing was not done. Three patients who underwent an early general anaesthetic experienced neurological deterioration; caution must be exercised when considering general anaesthesia for SURF1-deficient patients..

Although long-term survival in SURF1 deficiency is unusual, somewhat surprisingly we found that SURF1-deficient LS has a more favourable survival outcome compared to complex I-deficient LS or LRPPRC-deficient LS. Unlike SURF1 disease, LRPPRC deficiency is complicated by acute metabolic crises, which contribute significantly to the mortality \[[@B8]\].

Stepwise neurological regression often precipitated by illness and other states of high-energy demand, is thought to be part of the natural history of LS. In our cohort 6 patients surviving \>10 years did not experience developmental regression which suggests that developing effective therapeutic manoeuvres to prevent and treat episodic decompensation could improve the outcome in SURF1-deficient patients. However the prevention of decompensation may be challenging in instances where an obvious precipitant cannot be identified. It is difficult to comment about the effect of supportive therapies in SURF1 deficiency since there is insufficient treatment data available for this cohort to draw any meaningful conclusions. Recent candidate therapies such as EPI-743 are under evaluation and improvement in quality of life and motor function scores have been demonstrated in 2 SURF1-deficient patients recruited to an open-label phase 2A study \[[@B20]\].

We describe 5 novel mutations in addition to the 78 mutations found in the *SURF1* gene so far. Approximately 80% of the mutations found in SURF1 deficiency are truncating mutations resulting from aberrant splicing, frameshift deletions or nonsense mutations. Our study shows segregation of specific mutations within certain ethnic groups. The genotype distribution suggests founder effects for some mutations such as c.311_312insATdel10 in white Europeans and c.790_800delAG demonstrated in 3 different Bangladesh Bengali pedigrees. Previous reports indicate that c.604G \> C mutation has only been reported in Chinese individuals. We did not find a distinctive genotype-phenotype association although earlier reports \[[@B21]\] suggest missense *SURF1* mutations favour a better prognosis. It has not been possible to confirm this hypothesis in our cohort since only three subjects had missense mutations (1 homozygous, 2 compound heterozygous). However two of these patients are currently alive at 12 years and 17 years. The 7 patients described with milder phenotypes had varied genotypes including homozygosity for the common c.312_320del10insAT, suggesting that there are other factors which may influence survival.

We demonstrate that SURF1 deficiency has a distinct biochemical phenotype which includes consistently elevated CSF lactate, and decreased activities of COX in fibroblasts and muscle. Therefore when a typical clinical presentation of LS is encountered, if fibroblast COX activity is found to be low, targeted sequencing of the *SURF1* gene should be undertaken. If the patient is deteriorating rapidly it is prudent to perform a muscle biopsy with initial investigations since there are no distinctive clinical features of SURF1 deficiency which allow discrimination from other causes of LS. Muscle histochemistry shows uniform global reduction of COX activity but this may be very subtle and reported as normal since many centres use a prolonged incubation for COX histochemistry to allow maximum differentiation between COX-positive and negative fibres. Muscle histology demonstrated non-specific abnormalities such as lipid accumulation or fibre type disproportion (type I fibre predominance). Ragged red fibres which typically suggest a mitochondrial DNA mutation, have only been noted in two previous SURF1-deficient cases \[[@B14],[@B18]\] and were not found in any patients in our cohort. The clinical picture encountered in SURF1 deficiency is typical for LS, and it is only with a supportive biochemical picture such as low fibroblast and/or muscle COX activity that SURF1 deficiency can be suspected.

Previous reviews indicate that involvement of the subthalamic nucleus was a consistent finding on MRI in SURF1 disease \[[@B22]\]. In our study only 4 (12%) had lesions in the subthalamic nucleus. In contrast 16/33 (48%) patients had lesions in the putamen. The specificity of these lesions in SURF1 deficiency needs to be validated by comparison to other groups with LS. Most (85%) MRIs showed characteristic lesions of LS. Leukoencephalopathic changes were an atypical finding (n = 2) but SURF1 deficiency should not be overlooked in these cases \[[@B10]\]. The MRI was normal in 2 subjects at 1 year of age. Normal neuroradiology early in the disease may subsequently evolve to abnormality on repeat imaging \[[@B18]\].

The presence of a demyelinating peripheral neuropathy has been noted in previous cases in the literature \[[@B23],[@B24]\] and here we demonstrate that while in the majority of the cases the neuropathy is indeed of a demyelinating nature, an axonal neuropathy can be present.

Our study has several limitations. Although the study data were collected using a standardised questionnaire this is a retrospective study where clinical information was obtained by reviewing medical notes/case histories of patients, many now deceased. However it is unlikely that a large-scale prospective study will be conducted for this rare disease. The MRIs were performed at different centres and reviewed by different neuroradiologists which makes it difficult to ascribe specific patterns of disease. The MRI findings are based on a single scan in the majority of the cases and would only represent a snapshot of the neuroradiological changes but not disease progression. It is often not possible to capture these changes since repeated imaging in young children usually involves general anaesthetic with the attendant risks of metabolic decompensation.

Conclusions
===========

In conclusion, in contrast to other nuclear genes causing COX deficiency such as *SCO1*, *COX10* and *COX15*, SURF1 deficiency causes a largely homogeneous phenotype of LS characterised by systemic COX deficiency. To our knowledge, this is the first natural history study of SURF1 deficiency. Here we provide the most robust clinical description of the disease to date and a comprehensive account of all the genotypes and phenotypes reported so far. The prognostic and survival data in this study is based on a larger sample size than previous cohorts and will enable clinicians to be more confident when counselling families about the disease course. Advances in our understanding of the clinical spectrum and pathophysiology of SURF1 deficiency will be vital in planning therapeutic interventions in the future.
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